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Background: Non-small-cell lung cancers (NSCLCs) harboring translocations in anaplastic lymphoma kinase (ALK)
are highly sensitive to small-molecule ALK kinase inhibitors, such as crizotinib.
Case presentation: We describe a case of post-operative local recurrence of lung adenocarcinoma in an
81 year-old male. He underwent radiation and received chemotherapy with docetaxel, but neither treatment
regimen was effective. Following identification of ALK rearrangements, crizotinib treatment was initiated. After
treatment with crizotinib for 5 days, adverse events including acute renal failure (grade 2/CTCAE ver4.0) and
congestive heart failure (grade 3) occurred. Crizotinib modified treatment was required. Half dose of crizotinib
treatment could not control tumor progression. Ultimately, crizotinib was administrated at a dose of 250 mg
twice daily every 3 day dosing for 13 months with maintenance of the anti-tumor effect.
Conclusion: This is the first case report that skip schedule was more effective than dose reduction daily in
crizotinib administration for ALK rearranged NSCLC patient with severe adverse events.
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EML4-ALK (echinoderm microtubule-associated protein-
like 4 and the anaplastic lymphoma kinase) was recently
identified as a transforming fusion gene in non-small-cell
lung cancer (NSCLC) [1,2]. Approximately 2-7% of pa-
tients with NSCLC have rearrangements in the ALK gene,
leading to an oncogene-addicted state from aberrant ALK
activation [1,3]. Preclinical and clinical studies have shown
that cancer cells harboring EML4-ALK are highly sensitive
to ALK inhibition [4,5].
Crizotinib is the first clinically available ALK tyrosine kin-
ase inhibitor (TKI) and competes with ATP for binding to
the tyrosine kinase pocket of the enzyme, inhibiting tyro-
sine phosphorylation of activated ALK at nanomolar con-
centrations. The most common adverse events associated
with crizotinib include visual disturbances, gastrointestinal* Correspondence: mseike@nms.ac.jp
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unless otherwise stated.symptoms, peripheral edema, fatigue, decreased appetite,
and elevated aminotransferases [4,6]. The majority of the
toxicities are grade 1 or 2, and some improve with continu-
ation of therapy. Here, we present for the first time a case
in which every 3 day dosing administration of crizotinib
was effective and prevented adverse events in elderly
NSCLC harboring the ALK fusion gene.Case presentation
A 81 year-old male former-smoker who experienced
previously acute myocardial infarction presented in
January 2013 with mediastinal lymph node metastasis.
He was diagnosed as lung adenocarcinoma (AC) seven
years ago and underwent right-middle lobectomy and
lymph node-dissection (ND2a-1). His pathological stage
was stage IA (pT1bN0M0). The histopathological sub-
type of the specimen was mixed papillary and acinar
subtype AC components (Figure 1A). Immunohisto-
chemistry showed positive TTF-1, PE10, CD7, and
Alcian blue & PAS staining. In 2011, however, atral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 Histological and immunohistochemical findings in the primary tumor: (A) adenocarcinoma with mixed papillary and acinar subtype
(hematoxylin and eosin 40× magnification), (B) Immunohistochemical analysis of the ALK protein expression in the tumor cells, (C) Fluorescence






Figure 2 Chest radiograph and chest CT scan before (A and B) and after (C, D, E, F and G) crizotinib treatment: (A) Chest radiograph before
crizotinib therapy, (B) and swelling of the mediastinal lymph node (#4R), (C) chest radiograph after 5 days of crizotinib treatment revealing
increase in pleural effusions, (D) detection of right pleural effusions due to the appearance of congestive heart failure and renal failure, (E)
disappearance of pleural effusions and significant shrinking of the mediastinal lymph node. (F) CT scan just before the crizotinib re-challenge
after 4 months withdrawal. (G) CT scan after 3 months of the crizotinib re-challenging treatment.
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emission tomography-computed tomography (PET-CT)
scan showed mediastinal lymph node metastasis. Al-
though local recurrent mediastinal radiation therapy
(52 Gy) was performed, the mediastinal lymph metasta-
sis progressed. Therefore, in January 2013 the patient
received one cycle of chemotherapy with docetaxel in
consideration of elderly and the co-morbities. However,
the treatment was withdrawn because of serious upper
gastrointestinal bleeding due to the development of
hemorrhagic gastric ulcer during his medical course.
Mutation analysis revealed that the tumor expressed the
wild type epidermal growth factor receptor (EGFR) gene.
However, ALK rearrangements were identified using fluor-
escent in situ hybridization (FISH) and confirmed by im-
munohistochemistry for ALK expression in both tumors
(Figure 1B and C). Performance status (PS) was good (PS
1). We assessed that cytotoxic chemotherapy was high risk
because of short time from his recovery from the upper
gastrointestinal bleeding. Therefore, crizotinib was admin-
istered orally at a dose of 250 mg twice daily as a second-
line treatment (Figure 2A and B). After 5 days of crizotinib
therapy, the patient developed acutely deterioratingFigure 3 Changes in serum CEA and BNP levels after the resumption of firdyspnea and exhibited arterial oxygen desaturation and
hypoxemia (SpO2 89% in room air). Chest radiograph and
CT scan revealed increase of right pleural effusions
(Figure 2C and D). Serum B-type natriuretic peptide
(BNP) was increased from 134 to 314 pg/ml (Figure 3),
and creatinine (Cr) was elevated from 1.18 to 1.55 mg/dl.
The electrocardiogram was normal, showing no evidence
of arrhythmia, or acute myocardial infarction. Increased
levels of high sensitive Trop-T (0.024 ng/ml) and CK-Mb
(<4.0 ng/ml) were not found. Cardiac ultrasonography re-
vealed no abnormality (Ejection Fraction 78%). According
to the Framingham Study, we diagnosed his clinical mani-
festation, congestive heart failure and acute renal failure.
Since side effects of crizotinib were suspected, the drug
was immediately discontinued and started with furo-
semide 10 mg/day. Oxygenation, serum creatinine and
BNP immediately improved (Figure 3). Therefore, crizo-
tinib administration was resumed at 250 mg/day com-
bined with furosemide 10 mg/day.
Since there were no adverse events for 10 days, the
crizotinib dose was increased to 250 mg twice daily. By
following this regimen, the patient achieved significant
tumor response, as shown by CT scan (Figure 2E).stly crizotinib therapy.
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3 days and crizotinib therapy was once again discontinued.
One month later, the patient was re-challenged at a low
dose of 200 mg/day crizotinib therapy. Despite the dose re-
duction, pleural effusion and exacerbation of creatinine
(1.96 mg/dl) and BNP (274.7 pg/ml) occurred on day 11.
Four months later, as he had increased pleural effusion and
lymph node metastasis (Figure 2F), he was re-challenged
with 250 mg/day crizotinib administered every 3 days;
however, Carcinoembryonic antigen (CEA) was elevated
(Figure 4). Once again 250 mg/day drug was prescribed,
but no anti-tumor effect was observed. Administration of
250 mg twice daily was then tried on every other day, but
BNP levels increased (Figure 4). Finally, the frequency was
reduced to 250 mg twice daily every 3 day dosing, and
both BNP and CEA levels were decresed (Figure 4). Fi-
nally, a significant response was achieved without adverse
effects (Figure 2G). This treatment has been continued
with good response for 13 months.
Discussion
We report a rare case in which acute renal failure and
congestive heart failure occurred after the administrationFigure 4 Changes in serum CEA and BNP levels after the rechallenge of crof crizotinib for lung AC with ALK rearrangement, and
in which dose and schedule modification were required.
Because elevations in serum BNP, Cr and pleural effu-
sions were reversible on discontinuation of crizotinib,
these were recognized as adverse effects of crizotinib. To
our knowledge, no adverse effects on congestive heart fail-
ure patients have been described with crizotinib therapy in
previous clinical trials [4,6]. Renal toxicity of crizotinib has
previously been described (<10%) [7]. However, the patient
concerned was elderly and had exhibited a decline in car-
diac function following an occurrence of acute myocardial
infarction 10 years ago. By repetition of capacity modula-
tion, we have demonstrated the effectiveness of continuing
crizotinib therapy at a dose of 250 mg twice daily every
3 day dosing.
In EGFR-TKI treatment for advanced NSCLC with
EGFR mutation, some patients need a dose reduction of
gefitinib due to occurrence of several adverse effects. A
treatment strategy minimizing toxicity is especially re-
quired for patients in poor condition, or for elderly pa-
tients. A previous report demonstrated that low-dose
gefitinib may not be inferior to standard-dose gefitinib
for NSCLC patients with EGFR mutations [8]. On theizotinib therapy.
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ALK in whom successful clinical benefit without adverse
effects was observed by administration of crizotinib on
alternate days. Regarding a treatment schedule for crizo-
tinib, a previous case reported progression of brain me-
tastases under the use of standard crizotinib therapy
(250 mg twice daily); however, readjustment of crizotinib
dose to 500 mg once daily generated a favorable re-
sponse [9]. These authors hypothesized that increasing
the maximum plasma concentration (Cmax) without in-
creasing the daily dose of 500 mg could be beneficial.
Regarding pharmacokinetic-pharmacodynamic (PKPD)
simulation of crizotinib treatment, while Cmax was 243 ng/
ml for a once daily dose of crizotinib 400 mg, it was
493 ng/ml for a standard schedule of 250 mg twice daily
[10]. Taking into account the fact that the plasma half-life
was 29.1 hours for crizotinib 400 mg once daily, an effective
plasma concentration was preserved, since every 3 day dos-
ing administration of 250 mg twice daily may have pre-
vented excessive elevation of Cmax.
Conclusions
The present report indicates that alternate day adminis-
tration of crizotinib is a choice worth considering, since
it maintains sufficient clinical effects, while avoiding ser-
ious adverse events, especially in elderly and high-risk
cases. Every 3 day dosing administration may be an op-
tion but only in patients intolerant of standard dosing
trial.
Therefore, it is necessary to study the relationship be-
tween pharmacokinetics of crizotinib with every 3 day
dosing administration and clinical effects, as well as stand-
ard administration.
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